article thumbnail

Shorla gains FDA nod for first oral liquid version of Novartis' Gleevec

Fierce Pharma

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “am | Shorla Oncology has scored an FDA approval for its strawberry-flavored drink version of Novartis' cancer drug Gleevec. Dubbed Imkeldi, it becomes the first oral liquid form of imatinib.

FDA 293
article thumbnail

Number of ongoing US drug shortages reaches new high, pharmacist group says

Fierce Pharma

as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001. . | The American Society of Health-System Pharmacists has released new data showing there were 323 drugs in shortage in the U.S.

Biopharma 328
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lilly looks inward as it completes hunt for new CFO with appointment of 23-year vet Lucas Montarce

Fierce Pharma

Montarce, who’s been with the Indianapolis-based drugmaker since 2001, most recently worked as Lilly's president and general manager for the company’s hub in Spain, Portugal and Greece.

article thumbnail

Don’t blame mental health for mass murder

World of DTC Marketing

According to the National Institutes of Health, people with a mental health diagnosis committed less than 5 percent of gun-related homicides between 2001 and 2010.

article thumbnail

Regulatory-first for gene editing therapy

European Pharmaceutical Review

The Investigational New Drug (IND) application for Intellia Therapeutics’ in vivo CRISPR-based candidate NTLA-2001, has been cleared as a gene editing therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) in the US. This supports NTLA-2001’s potential as a single-administration therapeutic.

article thumbnail

W. Va. judge sides with drug distributors in bellwether opioid trial

MedCity News

From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 per 100,000. Judge finds no evidence of causation.

Biopharma 105
article thumbnail

Heart failure: clinical trials update 2022

European Pharmaceutical Review

NTLA-2001, a novel CRISPR/Cas9-based therapy in the first-ever human gene editing trial ( NCT04601051 ) in vivo (in the body), reduced transthyretin (TTR) proteins by at least 90 percent in amyloidogenic transthyretin (ATTR) cardiomyopathy patients, 28 days after a single IV infusion, with benefits lasting four to six months.

Safety 118